IL292018A - Formulations of highly lipophilic physiologically active substances with controlled release - Google Patents

Formulations of highly lipophilic physiologically active substances with controlled release

Info

Publication number
IL292018A
IL292018A IL292018A IL29201822A IL292018A IL 292018 A IL292018 A IL 292018A IL 292018 A IL292018 A IL 292018A IL 29201822 A IL29201822 A IL 29201822A IL 292018 A IL292018 A IL 292018A
Authority
IL
Israel
Prior art keywords
physiologically active
dosage form
active substances
highly lipophilic
form according
Prior art date
Application number
IL292018A
Other languages
English (en)
Hebrew (he)
Original Assignee
Add Advanced Drug Delivery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Add Advanced Drug Delivery Tech Ltd filed Critical Add Advanced Drug Delivery Tech Ltd
Publication of IL292018A publication Critical patent/IL292018A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL292018A 2019-10-16 2020-10-16 Formulations of highly lipophilic physiologically active substances with controlled release IL292018A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19203580.6A EP3808341A1 (de) 2019-10-16 2019-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen
PCT/EP2020/079248 WO2021074403A1 (de) 2019-10-16 2020-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen

Publications (1)

Publication Number Publication Date
IL292018A true IL292018A (en) 2022-06-01

Family

ID=68281185

Family Applications (1)

Application Number Title Priority Date Filing Date
IL292018A IL292018A (en) 2019-10-16 2020-10-16 Formulations of highly lipophilic physiologically active substances with controlled release

Country Status (10)

Country Link
US (1) US20240139215A1 (enExample)
EP (2) EP3808341A1 (enExample)
JP (2) JP7778069B2 (enExample)
CN (1) CN114945353A (enExample)
AU (1) AU2020365443B2 (enExample)
BR (1) BR112022006643A2 (enExample)
CA (1) CA3157654A1 (enExample)
IL (1) IL292018A (enExample)
MX (1) MX2022004523A (enExample)
WO (1) WO2021074403A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3808336A1 (de) * 2019-10-16 2021-04-21 ADD Advanced Drug Delivery Technologies, Ltd. Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen
AU2021400338A1 (en) 2020-12-17 2023-07-13 Nalu Bio, Inc. Synthesis of cannabidiol and analogs thereof, and related compounds, formulations, and methods of use
GB2618322A (en) * 2022-04-29 2023-11-08 113 Botanicals Ltd Compositions and methods
US12636296B1 (en) 2025-07-17 2026-05-26 Nalu Bio, Inc. Cannabinol analogs and their use as pharmacologically active agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
JPWO2002069957A1 (ja) * 2001-03-01 2004-07-02 グレラン製薬株式会社 フェノフィブラート含有組成物
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
US9943491B2 (en) 2013-10-29 2018-04-17 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
WO2015065547A1 (en) * 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
DE102014213548A1 (de) * 2014-07-11 2016-01-14 Hans Brammer Cannabispräparat
JP6581649B2 (ja) * 2014-08-11 2019-09-25 ペロラ ゲーエムベーハーＰｅｒｏｒａ Ｇｍｂｈ 粒子を含む製剤
IL246790A0 (en) * 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
US20190201350A1 (en) 2016-08-15 2019-07-04 Corr-Jensen Inc. Time release of fat-soluble actives
JP2019137614A (ja) * 2018-02-06 2019-08-22 富士フイルム株式会社 経口用医薬組成物及びその製造方法
DE102019100483A1 (de) * 2019-01-10 2020-07-16 Lts Lohmann Therapie-Systeme Ag Oraler Dünnfilm

Also Published As

Publication number Publication date
JP7778069B2 (ja) 2025-12-01
WO2021074403A1 (de) 2021-04-22
CA3157654A1 (en) 2021-04-22
CN114945353A (zh) 2022-08-26
AU2020365443A1 (en) 2022-06-02
EP3808341A1 (de) 2021-04-21
EP4045014A1 (de) 2022-08-24
US20240139215A1 (en) 2024-05-02
AU2020365443B2 (en) 2026-06-04
JP2022553653A (ja) 2022-12-26
JP2025182116A (ja) 2025-12-11
MX2022004523A (es) 2022-09-19
BR112022006643A2 (pt) 2022-07-12

Similar Documents

Publication Publication Date Title
US20240139215A1 (en) Controlled release formulations of highly lipophilic physiologically active substances
WO2021123804A1 (en) Oral cannabinoid formulations
US20230181484A1 (en) Uses and Formulations of Cannabinoids
FI78615C (fi) Foerfarande foer framstaellning av ett komplex av karragenan och anvaendningen av karragenan som komplexbildande medel foer emepron.
EP4405047A1 (en) Cannabinoid formulation for oral administration
IL292019A (en) Formulations of highly lipophilic physiologically active substances with controlled release
EP4667001A2 (en) Formulations of cannabinoids
US20230181485A1 (en) Uses and Formulations of Cannabinoids
US20230201284A1 (en) Uses and Formulations of Cannabinoids
EP4074307B1 (en) Formulations of cannabinoids
CN117715626A (zh) 大麻素的制剂